Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by brutus2005on May 05, 2010 1:54pm
377 Views
Post# 17065941

RE: science question

RE: science question<<< does doc moore have an idea now (based on incomplete results) on howthis is gonna turn out????  Could there be hints >>>

I think the biggest hint we've been given is the extension of the 50 cent warrants:

CALGARY, ALBERTA, Apr 16, 2010 (MARKETWIRE via COMTEX News Network) --

StemCell Therapeutics Corp. ("SCT") (TSX VENTURE: SSS) announces thereceipt of approval from the TSX Venture Exchange ("TSX-V") to extendthe expiry date of the
.50 warrants issued in conjunction with afinancing dated November 9, 2007 from May 9, 2010 to June 30, 2010.

Dr.Alan Moore, President and CEO of SCT commented as follows:

"Withour modified REGENISIS-LED enrolment completed and results expected inQ2, this extension will allow these warrant holders to make a moreinformed decision on exercising their warrants. If all remaining warrantholders from our November 2007 financing choose to exercise theirwarrants, this would provide $7.7 million to SCT without any financingfees or further issue of warrants."

Bullboard Posts